Table 2. Accessibility to high-cost anticancer medications in Peru.
| Anticancer medication | INEN (Lima) – MINSA | IREN North (Trujillo) – MINSA | IREN Central (Junín) – MINSA | IREN South (Arequipa) – MINSA | EsSalud |
|---|---|---|---|---|---|
| IV Trastuzumab | |||||
| SC Trastuzumab | |||||
| Pertuzumab 420 mg | |||||
| Lapatinib 250 mg | |||||
| Doxorubicin 50 mg | |||||
| Cyclophosphamide 1,000 mg | |||||
| Paclitaxel 100 mg | |||||
| Paclitaxel 30 mg | |||||
| Docetaxel 80 mg | |||||
| Docetaxel 20 mg | |||||
| Carboplatin 450 mg | |||||
| Carboplatin 150 mg | |||||
| Capecitabine 500 mg | |||||
| Liposomal doxorubicin 2 mg/mL/10 mL | |||||
| Ixabepilone | |||||
| Tamoxifen 20 mg | |||||
| Anastrozole 1 mg | |||||
| Exemestane 25 mg | |||||
| Fulvestrant 250 mg |
The nomenclature of IV trastuzumab used at INEN is 21 mg/mL. It is available in two packages (vials): Herceptin (440 mg/5 mL) and a biosimilar (Bisintex 420 mg/20 mL)
The SC trastuzumab vial is 120 mg/5 mL
Sources: Cherny NI, Sullivan R, Torode J, Saar M, et al. ESMO International Consortium Study on the availability, out-of-pocket cost and accessibility of anticancer medicines in countries outside of Europe; Pharmacy Department. National Institute of Neoplastic Diseases (INEN); Pharmacy Department. Ramiro Prialé Prialé National Hospital. EsSalud